IL6 and systemic-onset juvenile idiopathic arthritis: IL-6 trans-signalling has also been implicated in other diseases such as chronic inflammatory bowel disease and colon cancer [31], with a humanized monoclonal IL-6R antibody (tocilizumab) currently licensed for use in rheumatoid arthritis and systemic juvenile idiopathic arthritis [32].